There are currently 191 clinical trials in Jackson, Mississippi looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Mississippi Medical Center, Veterans Affairs Medical Center - Jackson, University of Mississippi Cancer Clinic and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662
Recruiting
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without a KMT2A gene rearrangement (KMT2A-germline \[G\]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoc... Read More
Gender:
ALL
Ages:
365 days and below
Trial Updated:
07/29/2025
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172
Recruiting
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/28/2025
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Intracranial Arteriosclerosis, Stroke
Register for Updates
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06799000
Recruiting
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: University of Mississippi Med Ctr, Jackson, Mississippi
Conditions: Hidradenitis Suppurativa
Register for Updates
ADVENT Post Approval Study
NCT06431815
Recruiting
The ADVENT Post Approval Study (PAS) is a prospective, global, multicenter, observational study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
NCT05677100
Recruiting
Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
07/28/2025
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
Register for Updates
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Jackson Oncology Associates - The Hederman Cancer Center, Jackson, Mississippi
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Register for Updates
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416
Recruiting
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be app... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University Of Mississippi Medical Center, Jackson, Mississippi +1 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288
Recruiting
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat and empagliflozin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Jackson Heart Clinic, P.A., Jackson, Mississippi
Conditions: Heart Failure
Register for Updates
Pivotal Study of Voro Urologic Scaffold
NCT06873581
Recruiting
The objective of this study is to compare safety and effectiveness of the Voro Urologic Scaffold in adult men undergoing robotic assisted radical prostatectomy as compared to control arm. The study is a multi-center, single blind, randomized, controlled trial. Up to 266 participants will be treated at up to 30 centers in the United States. The study will consist of a Baseline visit, implantation during robotic assisted radical prostatectomy (RARP), catheter removal, 6 weeks, 6 months, 12 months... Read More
Gender:
MALE
Ages:
45 years and above
Trial Updated:
07/25/2025
Locations: BMHCC/ Mississippi Urology Clinic, Jackson, Mississippi
Conditions: Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Register for Updates
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467
Recruiting
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: St. Dominic's Hospital ( Site 0064), Jackson, Mississippi
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Register for Updates
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374
Recruiting
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: The University of Mississippi Medical Center-Cancer Center and Research Institute ( Site 0043), Jackson, Mississippi
Conditions: Triple-Negative Breast Cancer
Register for Updates
The AIRTIVITY® Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892
Recruiting
This study is open to adults with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: University Of Mississippi Medical Center, Jackson, Mississippi
Conditions: Bronchiectasis
Register for Updates